Vigil Neuroscience Inc
VIGL8.060USD
+0.010+0.12%
交易中 （美东）报价延迟15分钟
376.17M总市值
亏损市盈率 TTM
关于 Vigil Neuroscience Inc 公司
Vigil Neuroscience, Inc. 是一家临床阶段的生物技术公司。该公司专注于通过恢复小胶质细胞（大脑的哨兵免疫细胞）的警觉性来开发罕见和常见神经退行性疾病的治疗方法。该公司正在利用现代神经科学药物开发工具，在多种治疗方式中努力开发精准疗法，以改善患者及其家人的生活。其主要临床候选药物 VGL101 (iluzanebart) 是一种完全人源单克隆抗体 TREM2 激动剂，目前正在对患有轴突球体和色素胶质细胞的成人发病性白质脑病患者进行 2 期概念验证试验。该公司还在开发 VG-3927，这是其口服小分子 TREM2 激动剂计划，用于治疗与小胶质细胞功能障碍相关的常见神经退行性疾病，最初的重点是基因定义的亚群中的阿尔茨海默病。
公司简介
公司代码VIGL
公司名称Vigil Neuroscience Inc
上市日期Jan 07, 2022
CEODr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
员工数量69
证券类型Ordinary Share
年结日Jan 07
公司地址100 Forge Road
城市WATERTOWN
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02472
电话18572544445
网址https://www.vigilneuro.com/
公司代码VIGL
上市日期Jan 07, 2022
CEODr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Samantha Budd Haeberlein, Ph.D.
Dr. Samantha Budd Haeberlein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Bruce L. Booth
Dr. Bruce L. Booth
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Dr. Cheryl Renee Blanchard, Ph.D.
Dr. Cheryl Renee Blanchard, Ph.D.
Independent Director
Independent Director
--
--
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
Dr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Petra Kaufmann, M.D.
Ms. Petra Kaufmann, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. David Gray, Ph.D.
Dr. David Gray, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Gerhard Koenig, Ph.D.
Dr. Gerhard Koenig, Ph.D.
Independent Director
Independent Director
--
--
Ms. Jennifer Ziolkowski, CPA
Ms. Jennifer Ziolkowski, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Stefan Vitorovic
Mr. Stefan Vitorovic
Independent Director
Independent Director
--
-100.00%
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Samantha Budd Haeberlein, Ph.D.
Dr. Samantha Budd Haeberlein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Bruce L. Booth
Dr. Bruce L. Booth
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Dr. Cheryl Renee Blanchard, Ph.D.
Dr. Cheryl Renee Blanchard, Ph.D.
Independent Director
Independent Director
--
--
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
Dr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Petra Kaufmann, M.D.
Ms. Petra Kaufmann, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月1日 周五
更新时间: 8月1日 周五
持股股东
股东类型
持股股东
持股股东
占比
Atlas Venture
12.51%
Beryl Capital Management, LLC
9.87%
BVF Partners L.P.
8.60%
Amgen Inc
6.87%
Glazer Capital, LLC
5.39%
Other
56.77%
持股股东
持股股东
占比
Atlas Venture
12.51%
Beryl Capital Management, LLC
9.87%
BVF Partners L.P.
8.60%
Amgen Inc
6.87%
Glazer Capital, LLC
5.39%
Other
56.77%
股东类型
持股股东
占比
Hedge Fund
33.86%
Venture Capital
17.21%
Investment Advisor
11.63%
Corporation
6.87%
Investment Advisor/Hedge Fund
3.73%
Individual Investor
0.51%
Research Firm
0.40%
Bank and Trust
0.17%
Other
25.62%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
167
34.72M
74.40%
-8.46M
2025Q1
155
37.71M
83.92%
-8.48M
2024Q4
145
40.31M
98.61%
+1.04M
2024Q3
142
37.92M
96.31%
-1.37M
2024Q2
139
36.35M
96.29%
-1.95M
2024Q1
131
36.78M
100.64%
+157.59K
2023Q4
124
35.04M
97.83%
-1.22M
2023Q3
117
35.82M
100.15%
-590.79K
2023Q2
111
36.00M
101.04%
+568.49K
2023Q1
103
35.28M
105.30%
-113.43K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Atlas Venture
5.84M
12.51%
--
--
Jun 11, 2025
Beryl Capital Management, LLC
4.61M
9.87%
+4.61M
--
May 22, 2025
BVF Partners L.P.
4.01M
8.6%
+2.20M
+121.30%
Mar 31, 2025
Amgen Inc
3.21M
6.87%
--
--
Jun 11, 2025
Glazer Capital, LLC
2.51M
5.39%
+2.51M
--
May 28, 2025
Invus Public Equities Advisors, LLC
1.97M
4.21%
-23.97K
-1.20%
Mar 31, 2025
683 Capital Management LLC
1.74M
3.73%
+340.00K
+24.29%
Mar 31, 2025
VV Manager LLC
1.63M
3.5%
-3.38M
-67.41%
Jun 11, 2025
Sphera Funds Management Ltd.
1.60M
3.44%
+102.00K
+6.79%
Mar 31, 2025
Ensign Peak Advisors, Inc.
1.58M
3.38%
+875.00K
+124.45%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
NYLI Merger Arbitrage ETF
0.2%
iShares Health Innovation Active ETF
0.1%
iShares Micro-Cap ETF
0.05%
Avantis US Small Cap Equity ETF
0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
查看更多
NYLI Merger Arbitrage ETF
占比0.2%
iShares Health Innovation Active ETF
占比0.1%
iShares Micro-Cap ETF
占比0.05%
Avantis US Small Cap Equity ETF
占比0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
占比0%
Proshares Ultra Russell 2000
占比0%
iShares Russell 2000 Value ETF
占比0%
iShares Russell 2000 ETF
占比0%
Global X Russell 2000 ETF
占比0%
ProShares Hedge Replication ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
